ELI LILLY AND COMPANY Derivative Liability, Notional Amount
ELI LILLY AND COMPANY (LLY) had Derivative Liability, Notional Amount of $1.35 billion as of 2015-02-27, per its 10-K filed 2016-02-19.
Discontinued › Notes › Derivative Instruments and Hedging Activities
us-gaap:DerivativeLiabilityNotionalAmount · last filed 2016-02-19
- 2015-02-27: Derivative Liability, Notional Amount $1.35B.
| Period end | Derivative Liability, Notional Amount |
|---|---|
| 2015-02-27 | $1.35B 10-K · filed 2016-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |